GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Debt-to-Revenue

Daiichinkyo Co (Daiichinkyo Co) Debt-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3 Mil. Daiichinkyo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $676 Mil. Daiichinkyo Co's annualized Revenue for the quarter that ended in Mar. 2024 was $11,438 Mil. Daiichinkyo Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.

Daiichinkyo Co Debt-to-Revenue Historical Data

The historical data trend for Daiichinkyo Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Debt-to-Revenue Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.19 0.16 0.11 0.06

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.11 0.08 0.06 0.06

Competitive Comparison of Daiichinkyo Co's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Debt-to-Revenue falls into.


Daiichinkyo Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Daiichinkyo Co's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.663 + 676.244) / 10690.849
=0.06

Daiichinkyo Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.663 + 676.244) / 11438.34
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Daiichinkyo Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Debt-to-Revenue
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSNKY:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.